Literature DB >> 11602747

Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

J S Kahn1, A Roberts, C Weibel, L Buonocore, J K Rose.   

Abstract

Foreign glycoproteins expressed in recombinant vesicular stomatitis virus (VSV) can elicit specific and protective immunity in the mouse model. We have previously demonstrated the expression of respiratory syncytial virus (RSV) G (attachment) and F (fusion) glycoprotein genes in recombinant VSV. In this study, we demonstrate the expression of RSV F and G glycoproteins in attenuated, nonpropagating VSVs which lack the VSV G gene (VSVDeltaG) and the incorporation of these RSV proteins into recombinant virions. We also show that intranasal vaccination of mice with nondefective VSV recombinants expressing RSV G (VSV-RSV G) or RSV F (VSV-RSV F) elicited RSV-specific antibodies in serum (by enzyme-linked immunosorbent assay [ELISA]) as well as neutralizing antibodies to RSV and afford complete protection against RSV challenge. In contrast, VSVDeltaG-RSV F induced detectable serum antibodies to RSV by ELISA, but no detectable neutralizing antibodies, yet it still protected from RSV challenge. VSVDeltaG-RSV G failed to induce any detectable serum (by ELISA) or neutralizing antibodies and failed to protect from RSV challenge. The attenuated, nonpropagating VSVDeltaG-RSV F is a particularly attractive candidate for a live attenuated recombinant RSV vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602747      PMCID: PMC114687          DOI: 10.1128/JVI.75.22.11079-11087.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Epidemiology of acute lower respiratory disease in children.

Authors:  P Glezen; F W Denny
Journal:  N Engl J Med       Date:  1973-03-08       Impact factor: 91.245

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

5.  Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.

Authors:  A Boelen; A Andeweg; J Kwakkel; W Lokhorst; T Bestebroer; J Dormans; T Kimman
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

6.  Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.

Authors:  N F Rose; A Roberts; L Buonocore; J K Rose
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Authors:  P F Wright; R A Karron; R B Belshe; J Thompson; J E Crowe; T G Boyce; L L Halburnt; G W Reed; S S Whitehead; E L Anderson; A E Wittek; R Casey; M Eichelberger; B Thumar; V B Randolph; S A Udem; R M Chanock; B R Murphy
Journal:  J Infect Dis       Date:  2000-09-22       Impact factor: 5.226

8.  Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus.

Authors:  C L Lamprecht; H E Krause; M A Mufson
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

9.  Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

Authors:  P A Piedra; S Grace; A Jewell; S Spinelli; D Bunting; D A Hogerman; F Malinoski; P W Hiatt
Journal:  Pediatr Infect Dis J       Date:  1996-01       Impact factor: 2.129

Review 10.  Respiratory viral infections in immunocompetent and immunocompromised persons.

Authors:  R B Couch; J A Englund; E Whimbey
Journal:  Am J Med       Date:  1997-03-17       Impact factor: 4.965

View more
  56 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

Review 2.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 3.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

4.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection.

Authors:  Xiaodan Shi; Jingping Hu; Jing Guo; Chuanjian Wu; Sidong Xiong; Chunsheng Dong
Journal:  Virol Sin       Date:  2019-02-28       Impact factor: 4.327

6.  Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Authors:  Heather J Ezelle; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus.

Authors:  Jessica Leung; Frank Esper; Carla Weibel; Jeffrey S Kahn
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.

Authors:  Anasuya Chattopadhyay; Eryu Wang; Robert Seymour; Scott C Weaver; John K Rose
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.